Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Andrés A Trabanco, José Manuel Bartolomé & José María Cid. (2019) mGluR2 positive allosteric modulators: an updated patent review (2013–2018). Expert Opinion on Therapeutic Patents 29:7, pages 497-507.
Read now
Read now
Andrés A Trabanco & José María Cid. (2013) mGluR2 positive allosteric modulators: a patent review (2009 – present). Expert Opinion on Therapeutic Patents 23:5, pages 629-647.
Read now
Read now
Articles from other publishers (35)
Susan F. Sonnenschein & Anthony A. Grace. (2020) Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia. Neuropharmacology 163, pages 107632.
Crossref
Crossref
Andrea de Bartolomeis, Camilla Avagliano, Licia Vellucci, Luigi D’Ambrosio, Mirko Manchia, Giordano D’Urso, Elisabetta Filomena Buonaguro & Felice Iasevoli. (2019) Translating preclinical findings in clinically relevant new antipsychotic targets: focus on the glutamatergic postsynaptic density. Implications for treatment resistant schizophrenia. Neuroscience & Biobehavioral Reviews 107, pages 795-827.
Crossref
Crossref
L. Lundström, C. Bissantz, J. Beck, M. Dellenbach, T.J. Woltering, J. Wichmann & S. Gatti. (2017) Reprint of Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2. Neuropharmacology 115, pages 115-127.
Crossref
Crossref
Maria-Jesus Blanco, Dana R. Benesh, James A. Knobelsdorf, Albert Khilevich, Guillermo S. Cortez, Fese Mokube, Thomas D. Aicher, Todd M. Groendyke, Fredrik P. Marmsater, Tony P. Tang, Kirk W. Johnson, Amy Clemens-Smith, Mark A. Muhlhauser, Steven Swanson, John Catlow, Renee Emkey, Michael P. Johnson & Jeffrey M. Schkeryantz. (2017) Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headache. Bioorganic & Medicinal Chemistry Letters 27:2, pages 323-328.
Crossref
Crossref
L. Lundström, C. Bissantz, J. Beck, M. Dellenbach, T.J. Woltering, J. Wichmann & S. Gatti. (2016) Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2. Neuropharmacology 111, pages 253-265.
Crossref
Crossref
Guy Griebel, Philippe Pichat, Denis Boulay, Vanessa Naimoli, Lisa Potestio, Robert Featherstone, Sukhveen Sahni, Henry Defex, Christophe Desvignes, Franck Slowinski, Xavier Vigé, Olivier E. Bergis, Rosy Sher, Raymond Kosley, Sathapana Kongsamut, Mark D. Black & Geoffrey B. Varty. (2016) The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia. Scientific Reports 6:1.
Crossref
Crossref
Lei Sheng, Ling Wang, Mingyu Su, Xiaoyang Zhao, Renping Hu, Xiaohong Yu, Jie Hong, Dong Liu, Bingqing Xu, Yunting Zhu, Han Wang & Fashui Hong. (2016)
Mechanism of TiO
2
nanoparticle-induced neurotoxicity in zebrafish (
D
anio rerio
)
. Environmental Toxicology 31:2, pages 163-175.
Crossref
Crossref
Abdallah Ahnaou, Hilde Lavreysen, Gary Tresadern, Jose M. Cid & Wilhelmus H. Drinkenburg. (2015) mGlu2 Receptor Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards Their Primary Efficacy on Sleep Measures in Rats. PLOS ONE 10:12, pages e0144017.
Crossref
Crossref
James A. Monn, Lourdes Prieto, Lorena Taboada, Junliang Hao, Matthew R. Reinhard, Steven S. Henry, Christopher D. Beadle, Lesley Walton, Teresa Man, Helene Rudyk, Barry Clark, David Tupper, S. Richard Baker, Carlos Lamas, Carlos Montero, Alicia Marcos, Jaime Blanco, Mark Bures, David K. Clawson, Shane Atwell, Frances Lu, Jing Wang, Marijane Russell, Beverly A. Heinz, Xushan Wang, Joan H. Carter, Brian G. Getman, John T. Catlow, Steven Swanson, Bryan G. Johnson, David B. Shaw & David L. McKinzie. (2015)
Synthesis and Pharmacological Characterization of
C
4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1
R
,2
S
,4
R
,5
R
,6
R
)-2-Amino-4-(1
H
-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu
2
Receptor Agonist
. Journal of Medicinal Chemistry 58:18, pages 7526-7548.
Crossref
Crossref
James A. Monn, Lourdes Prieto, Lorena Taboada, Concepcion Pedregal, Junliang Hao, Matt R. Reinhard, Steven S. Henry, Paul J. Goldsmith, Christopher D. Beadle, Lesley Walton, Teresa Man, Helene Rudyk, Barry Clark, David Tupper, S. Richard Baker, Carlos Lamas, Carlos Montero, Alicia Marcos, Jaime Blanco, Mark Bures, David K. Clawson, Shane Atwell, Frances Lu, Jing Wang, Marijane Russell, Beverly A. Heinz, Xushan Wang, Joan H. Carter, Chuanxi Xiang, John T. Catlow, Steven Swanson, Helen Sanger, Lisa M. Broad, Michael P. Johnson, Kelly L. Knopp, Rosa M. A. Simmons, Bryan G. Johnson, David B. Shaw & David L. McKinzie. (2015)
Synthesis and Pharmacological Characterization of C4-Disubstituted Analogs of 1
S
,2
S
,5
R
,6
S
-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: Identification of a Potent, Selective Metabotropic Glutamate Receptor Agonist and Determination of Agonist-Bound Human mGlu2 and mGlu3 Amino Terminal Domain Structures
. Journal of Medicinal Chemistry 58:4, pages 1776-1794.
Crossref
Crossref
Tetsuaki Hiyoshi, Toshiyuki Marumo, Hirohiko Hikichi, Yasumitsu Tomishima, Hiroki Urabe, Tomoko Tamita, Izumi Iida, Akito Yasuhara, Jun-ichi Karasawa & Shigeyuki Chaki. (2014) Neurophysiologic and Antipsychotic Profiles of TASP0433864, a Novel Positive Allosteric Modulator of Metabotropic Glutamate 2 Receptor. Journal of Pharmacology and Experimental Therapeutics 351:3, pages 642-653.
Crossref
Crossref
E. V. Radchenko, D. S. Karlov, V. A. Palyulin & N. S. Zefirov. (2014) Molecular modeling of the transmembrane domain of mGluR2 metabotropic glutamate receptor and the binding site of its positive allosteric modulators. Doklady Biochemistry and Biophysics 454:1, pages 13-16.
Crossref
Crossref
José M. Cid, Andrés A. Trabanco & Hilde Lavreysen. 2015. Small Molecule Therapeutics for Schizophrenia. Small Molecule Therapeutics for Schizophrenia
101
142
.
Christopher L. Cioffi. (2013) Modulation of NMDA receptor function as a treatment for schizophrenia. Bioorganic & Medicinal Chemistry Letters 23:18, pages 5034-5044.
Crossref
Crossref
Min-Juan Wang, Yan-Chun Li, Melissa A. Snyder, Huaixing Wang, Feng Li & Wen-Jun Gao. (2013) Group II Metabotropic Glutamate Receptor Agonist LY379268 Regulates AMPA Receptor Trafficking in Prefrontal Cortical Neurons. PLoS ONE 8:4, pages e61787.
Crossref
Crossref
Daniela Durand, Lila Carniglia, Carla Caruso & Mercedes Lasaga. (2013) mGlu3 receptor and astrocytes: Partners in neuroprotection. Neuropharmacology 66, pages 1-11.
Crossref
Crossref
Gerard J. Marek, Bruce J. Kinon, David L. McKinzie, Jeffrey M. Schkeryantz & James A. Monn. 2012. Targets and Emerging Therapies for Schizophrenia. Targets and Emerging Therapies for Schizophrenia
143
185
.
Richard M. Cleva & M. Foster Olive. (2012) Metabotropic glutamate receptors and drug addiction. Wiley Interdisciplinary Reviews: Membrane Transport and Signaling 1:3, pages 281-295.
Crossref
Crossref
Matthew J. Fell, David L. McKinzie, James A. Monn & Kjell A. Svensson. (2012) Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology 62:3, pages 1473-1483.
Crossref
Crossref
Paige N. Vinson & P. Jeffrey Conn. (2012) Metabotropic glutamate receptors as therapeutic targets for schizophrenia. Neuropharmacology 62:3, pages 1461-1472.
Crossref
Crossref
Sylvain Célanire, Guillaume Duvey, Sonia Poli & Jean-Philippe Rocher. 2012. Annual Reports in Medicinal Chemistry Volume 47. Annual Reports in Medicinal Chemistry Volume 47
71
88
.
E. J. Herman, M. Bubser, P. J. Conn & C. K. Jones. 2012. Novel Antischizophrenia Treatments. Novel Antischizophrenia Treatments
297
365
.
Daniela Durand, Lila Carniglia & Mercedes Lasaga. (2012) mGlu receptors in endocrine organs. Wiley Interdisciplinary Reviews: Membrane Transport and Signaling 1:1, pages 78-84.
Crossref
Crossref
L Lundström, C Bissantz, J Beck, JG Wettstein, TJ Woltering, J Wichmann & S Gatti. (2011) Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators. British Journal of Pharmacology 164:2b, pages 521-537.
Crossref
Crossref
Douglas J. Sheffler, Anthony B. Pinkerton, Russell Dahl, Athina Markou & Nicholas D. P. Cosford. (2011) Recent Progress in the Synthesis and Characterization of Group II Metabotropic Glutamate Receptor Allosteric Modulators. ACS Chemical Neuroscience 2:8, pages 382-393.
Crossref
Crossref
Val?rie Panneels, Ines Kock, Jacomine Krijnse-Locker, Meriem Rezgaoui & Irmgard Sinning. (2011) Drosophila Photoreceptor Cells Exploited for the Production of Eukaryotic Membrane Proteins: Receptors, Transporters and Channels. PLoS ONE 6:4, pages e18478.
Crossref
Crossref
Lei Zhang, Michael A. Brodney, John Candler, Angela C. Doran, Allen J. Duplantier, Ivan V. Efremov, Edel Evrard, Kenneth Kraus, Alan H. Ganong, Jessica A. Haas, Ashley N. Hanks, Keith Jenza, John T. Lazzaro, Noha Maklad, Sheryl A. McCarthy, Weimin Qian, Bruce N. Rogers, Melinda D. Rottas, Christopher J. Schmidt, Judith A. Siuciak, F. David TingleyIIIIII & Andy Q. Zhang. (2011)
1-[(1-Methyl-1
H
-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 Positive Allosteric Modulators for the Treatment of Psychosis
. Journal of Medicinal Chemistry 54:6, pages 1724-1739.
Crossref
Crossref
F. Caraci, G. Molinaro, G. Battaglia, M. L. Giuffrida, B. Riozzi, A. Traficante, V. Bruno, M. Cannella, S. Merlo, X. Wang, B. A. Heinz, E. S. Nisenbaum, T. C. Britton, F. Drago, M. A. Sortino, A. Copani & F. Nicoletti. (2010) Targeting Group II Metabotropic Glutamate (mGlu) Receptors for the Treatment of Psychosis Associated with Alzheimer's Disease: Selective Activation of mGlu2 Receptors Amplifies -Amyloid Toxicity in Cultured Neurons, Whereas Dual Activation of mGlu2 and mGlu3 Receptors Is Neuroprotective. Molecular Pharmacology 79:3, pages 618-626.
Crossref
Crossref
Barbara Wroblewska, Iga N. Wegorzewska, Tomasz Bzdega & Joseph H. Neale. (2011) Type 2 metabotropic glutamate receptor (mGluR2) fails to negatively couple to cGMP in stably transfected cells. Neurochemistry International 58:2, pages 176-179.
Crossref
Crossref
Andrés A. Trabanco, Guillaume Duvey, José María Cid, Gregor J. Macdonald, Philippe Cluzeau, Vanthea Nhem, Rocco Furnari, Nadia Behaj, Géraldine Poulain, Terry Finn, Sonia Poli, Hilde Lavreysen, Alexandre Raux, Yves Thollon, Nicolas Poirier, David D'Addona, José Ignacio Andrés, Robert Lutjens, Emmanuel Le Poul, Hassan Imogai & Jean-Philippe Rocher. (2011) New positive allosteric modulators of the metabotropic glutamate receptor 2 (mGluR2). Identification and synthesis of N-propyl-5-substituted isoquinolones. Med. Chem. Commun. 2:2, pages 132-139.
Crossref
Crossref
Robert M. Garbaccio, Edward J. Brnardic, Mark E. Fraley, George D. Hartman, Pete H. Hutson, Julie A. O'Brien, Brian C. Magliaro, Jason M. Uslaner, Sarah L. Huszar, Kerry L. Fillgrove, James H. Small, Cuyue Tang, Yuhsin Kuo & Marlene A. Jacobson. (2010) Discovery of Oxazolobenzimidazoles as Positive Allosteric Modulators for the mGluR2 Receptor. ACS Medicinal Chemistry Letters 1:8, pages 406-410.
Crossref
Crossref
Edward J. Brnardic, Mark E. Fraley, Robert M. Garbaccio, Mark E. Layton, John M. Sanders, Chris Culberson, Marlene A. Jacobson, Brian C. Magliaro, Pete H. Hutson, Julie A. O’Brien, Sarah L. Huszar, Jason M. Uslaner, Kerry L. Fillgrove, Cuyue Tang, Yuhsin Kuo, Sylvie M. Sur & George D. Hartman. (2010) 3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts. Bioorganic & Medicinal Chemistry Letters 20:10, pages 3129-3133.
Crossref
Crossref
Gregor J. Macdonald & José Manuel Bartolomé. 2010.
37
80
.
Douglas J. Sheffler & P. Jeffrey Conn. 2010. Glutamate-based Therapies for Psychiatric Disorders. Glutamate-based Therapies for Psychiatric Disorders
101
116
.
Eric Schaeffer & Allen Duplantier. 2010. Neurodegenerative Diseases. Neurodegenerative Diseases
91
147
.